Press Releases Events & Presentations Event Details AASLD – The Liver Meeting® 2023 Nov 10 - Nov 14, 2023 Supporting Materials IFNAR – In Vitro and in Vivo Profiling of Orally Bioavailable Small Molecules Inhibiting Hepatitis B Virus by Mimicking Interferon Alpha (Poster) 1.3 MB Vebicorvir – Preliminary Off-Treatment Responses Following 48 Weeks of Vebicorvir, Nucleos(t)ide Reverse Transcriptase Inhibitor, and AB-729 Combination in Virologically Suppressed Patients With Hepatitis B e Antigen Negative Chronic Hepatitis B: Analysis 341 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
AASLD – The Liver Meeting® 2023 Nov 10 - Nov 14, 2023 Supporting Materials IFNAR – In Vitro and in Vivo Profiling of Orally Bioavailable Small Molecules Inhibiting Hepatitis B Virus by Mimicking Interferon Alpha (Poster) 1.3 MB Vebicorvir – Preliminary Off-Treatment Responses Following 48 Weeks of Vebicorvir, Nucleos(t)ide Reverse Transcriptase Inhibitor, and AB-729 Combination in Virologically Suppressed Patients With Hepatitis B e Antigen Negative Chronic Hepatitis B: Analysis 341 KB
IFNAR – In Vitro and in Vivo Profiling of Orally Bioavailable Small Molecules Inhibiting Hepatitis B Virus by Mimicking Interferon Alpha (Poster) 1.3 MB
Vebicorvir – Preliminary Off-Treatment Responses Following 48 Weeks of Vebicorvir, Nucleos(t)ide Reverse Transcriptase Inhibitor, and AB-729 Combination in Virologically Suppressed Patients With Hepatitis B e Antigen Negative Chronic Hepatitis B: Analysis 341 KB
